Infection News

Influenza vaccination coverage in adults with early rheumatoid arthritis in Canada remains “suboptimal,” according to data published in ACR Open Rheumatology.

The COVID-19 pandemic had an overall negative impact on rheumatology training, with 25% reporting they did not feel physically safe in the workplace, according to poster data published in Annals of the Rheumatic Diseases.

Children and adolescents with rheumatic and musculoskeletal diseases who contract COVID-19 are not likely to require hospitalization, according to data published in the Annals of the Rheumatic Diseases.

Patients receiving mycophenolate mofetil combination therapies saw increased seroconversion after a third dose of SARS-CoV-2 vaccine, while patients on anti-CD20 and S1P modulators saw little impact from a third dose, researchers noted.

More than 40% of patients with long COVID experience “fibromyalgia-like,” multisite pain, according to data released by Tonix Pharmaceuticals.

When the CDC released new masking guidance at the end of February, it seemed to indicate a shift toward treating COVID-19 as something people will learn to live with.

Northeastern cities, including New York and Washington, D.C., have seen a surge in COVID-19 cases, but increased immunization, low hospitalization rates and a growing armamentarium against infection may serve to temper calls for alarm.

Older children and those with ferritin levels greater than 500 µg/L are at highest risk for severe multisystem inflammatory syndrome in children resulting in ICU admission after COVID-19, according to data published in CMAJ.

The Pfizer-BioNTech mRNA vaccine for COVID-19 is safe for patients with familial Mediterranean fever, according to data published in Rheumatology.

The FDA has granted priority review for intravenous tocilizumab to treat adults hospitalized with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation.